Casdozokitug not checked

Coherus Oncology, Inc. · CHS-388 · SRF388

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
Tested for
Hepatocellular Carcinoma
Main trialPhase 2
“The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.”In the company’s words, NCT06679985 on ClinicalTrials.gov
Other names
CHS-388 · SRF388

Other drugs for Hepatocellular Carcinoma

All 130 drugs for Hepatocellular Carcinoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Sep 2027 A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Phase 2Terminated 30 Jun 2025 Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
Phase 1Completed 28 May 2025 Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Casdozokitug

Following is part of Solo: you see every change to Casdozokitug the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in